Taiyen Biotech Co., Ltd.
TWSE:1737.TW
31.6 (TWD) • At close January 15, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,408.811 | 3,613.607 | 4,095.651 | 3,130.347 | 2,906.615 | 3,001.462 | 2,757.075 | 2,755.185 | 2,761.204 | 2,597.177 | 2,408.819 | 2,296.293 | 2,298.251 | 2,152.877 | 1,980.143 |
| Cost of Revenue
| 2,199.1 | 2,337.002 | 2,722.415 | 1,822.755 | 1,696.299 | 1,800.389 | 1,618.218 | 1,606.345 | 1,718.895 | 1,680.388 | 1,581.837 | 1,523.697 | 1,319.928 | 1,207.999 | 1,206.302 |
| Gross Profit
| 1,209.711 | 1,276.605 | 1,373.236 | 1,307.592 | 1,210.316 | 1,201.073 | 1,138.857 | 1,148.84 | 1,042.309 | 916.789 | 826.982 | 772.596 | 978.323 | 944.878 | 773.841 |
| Gross Profit Ratio
| 0.355 | 0.353 | 0.335 | 0.418 | 0.416 | 0.4 | 0.413 | 0.417 | 0.377 | 0.353 | 0.343 | 0.336 | 0.426 | 0.439 | 0.391 |
| Reseach & Development Expenses
| 60.495 | 60.64 | 57.597 | 73.984 | 68.618 | 58.465 | 57.47 | 53.659 | 54.112 | 56.706 | 64.883 | 60.731 | 61.725 | 56.507 | 40.685 |
| General & Administrative Expenses
| 212.485 | 217.234 | 217.99 | 212.176 | 200.293 | 215.828 | 188.529 | 174.477 | 174.543 | 155.602 | 152.71 | 157.042 | 153.61 | 154.193 | 155.249 |
| Selling & Marketing Expenses
| 589.498 | 553.681 | 568.472 | 558.111 | 521.647 | 508.278 | 474.77 | 510.881 | 504.358 | 539.518 | 506.695 | 506.885 | 532.92 | 504.804 | 351.739 |
| SG&A
| 836.559 | 770.915 | 786.462 | 770.287 | 721.94 | 724.106 | 663.299 | 685.358 | 678.901 | 695.12 | 659.405 | 663.927 | 686.53 | 658.997 | 506.988 |
| Other Expenses
| 0 | 90.06 | -13.317 | 4.877 | 12.94 | 114.86 | 8.38 | 8.425 | 12.858 | 80.803 | 47.813 | -5.008 | 4.163 | -6.924 | -31.782 |
| Operating Expenses
| 897.054 | 831.555 | 844.059 | 844.271 | 790.558 | 782.571 | 720.769 | 739.017 | 733.013 | 751.826 | 727.691 | 724.658 | 748.255 | 715.504 | 547.673 |
| Operating Income
| 312.657 | 535.11 | 515.86 | 467.644 | 430.942 | 418.502 | 418.088 | 409.823 | 309.296 | 164.963 | 99.291 | 47.938 | 230.068 | 229.374 | 226.168 |
| Operating Income Ratio
| 0.092 | 0.148 | 0.126 | 0.149 | 0.148 | 0.139 | 0.152 | 0.149 | 0.112 | 0.064 | 0.041 | 0.021 | 0.1 | 0.107 | 0.114 |
| Total Other Income Expenses Net
| 16.459 | -4.523 | -19.259 | -11.496 | -3.311 | 113.088 | 8.39 | 4.996 | 10.042 | 80.795 | 40.843 | 34.933 | 15.434 | -5.144 | 57.445 |
| Income Before Tax
| 329.116 | 530.587 | 509.918 | 464.039 | 428.547 | 531.59 | 426.478 | 414.819 | 319.338 | 245.758 | 143.537 | 78.209 | 232.637 | 224.23 | 283.613 |
| Income Before Tax Ratio
| 0.097 | 0.147 | 0.125 | 0.148 | 0.147 | 0.177 | 0.155 | 0.151 | 0.116 | 0.095 | 0.06 | 0.034 | 0.101 | 0.104 | 0.143 |
| Income Tax Expense
| 111.82 | 103.071 | 97.756 | 89.45 | 83.044 | 78.849 | 72.784 | 62.852 | 50.408 | 31.289 | 17.583 | 0.104 | 38.57 | 42.82 | 73.845 |
| Net Income
| 300.386 | 426.704 | 393.227 | 365.085 | 345.503 | 452.741 | 353.694 | 351.967 | 268.93 | 214.469 | 125.954 | 78.105 | 194.067 | 181.41 | 209.768 |
| Net Income Ratio
| 0.088 | 0.118 | 0.096 | 0.117 | 0.119 | 0.151 | 0.128 | 0.128 | 0.097 | 0.083 | 0.052 | 0.034 | 0.084 | 0.084 | 0.106 |
| EPS
| 1.5 | 2.13 | 1.97 | 1.83 | 1.73 | 2.26 | 1.77 | 1.76 | 1.34 | 1.07 | 0.46 | 0.29 | 0.97 | 0.9 | 1.04 |
| EPS Diluted
| 1.5 | 2.13 | 1.96 | 1.82 | 1.72 | 2.26 | 1.76 | 1.75 | 1.34 | 1.07 | 0.46 | 0.28 | 0.97 | 0.9 | 1.04 |
| EBITDA
| 518.265 | 717.563 | 706.366 | 641.992 | 591.946 | 691.941 | 575.061 | 571.571 | 478.209 | 384.604 | 275.672 | 206.54 | 345.176 | 341.582 | 342.075 |
| EBITDA Ratio
| 0.152 | 0.202 | 0.172 | 0.209 | 0.207 | 0.234 | 0.213 | 0.211 | 0.173 | 0.148 | 0.116 | 0.065 | 0.157 | 0.157 | 0.129 |